Bone Metabolism Therapeutics Market Analysed Through 2018 by GBI Research

03 Jul 2012 • by Natalie Aster

At present the bone metastases market is a low-growth market because it is adequately served by the currently available treatment options. The current market has three drugs approved for the treatment of hyperparathyroidism: Sensipar, Zemplar (paricalcitol) and Hectorol (doxercalciferol). It is estimated that the market will decline at a negative CAGR of 1.3% down to $1.17 billion in 2018 due to the patent expirations of all the three approved drugs within the forecast period.

However, the pipeline still has the potential to uncover opportunities for new entrants. Its therapeutics pipeline is strong, with 47 molecules in various phases of clinical development, many of which are First-in-Class (FIC). Of these, three are in late-stage development and the rest are in early-stage development. The European Commission (EC) has already granted marketing authorization of Xeva in the European Union and it is expected to have a strong impact on the European market. Alpharadin, is a radiopharmaceutical which is expected to be launched by 2014 and Orazol, currently in Phase III, is a once-weekly oral formulation of zoledronic acid that is also expected to reach the market by 2014. The new report "Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar" by GBI Research states that both Alpharadin and Orazol are expected to be responsible for the growth of the bone metastases therapeutics market in the next few years.

Report Details:

Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar
Published: June, 2012
Pages: 112
Price: US$ 3.500,00

This report provides an in-depth analysis of the major bone metabolic diseases, including osteoporosis, Paget's disease of bone, hyperparathyroidism and bone metastases. It also provides the share of generics in global bone metabolic diseases as well as in each indication market and the treatment algorithm flow for each of the four indications. The report examines the global bone metabolic diseases treatment usage patterns. In addition, the geographical distribution of bone metabolic diseases and markets across the US, the top five countries of Europe, and in Japan, are provided in the report. Insights into the bone metabolic diseases R&D product pipelin are included along with the competitive landscape, including major players in the bone metabolism therapeutics market. Analysis of Mergers and Acquisitions (M&As) and licensing agreements that took place in the bone metabolism therapeutics market is also provided.

More information can be found in the report “Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar” by GBI Research.

To order the report or ask for sample pages contact ps@marketpublishers.com

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com